Evidence map›Paper›PMID 38563006›Full record

ArticlePeerJ2024

Factors associated with intention to be vaccinated with the COVID-19 booster dose: a cross-sectional study in Peru.

Rodrigo Camacho-Neciosup, Ericka N Balcazar-Huaman, Margarita L Alvarez-Vilchez, Janith P De la Cruz-Galán, Yubely Gálvez-Guadalupe, Edwin D Garcia-Muñoz, Greysi Cerron-Daga, Virgilio E Failoc-Rojas, Mario J Valladares-Garrido

Abstract read
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rodrigo Camacho-NeciosupSociedad Científica de Estudiantes de Medicina, Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru.
Ericka N Balcazar-HuamanSociedad Científica de Estudiantes de Medicina, Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru.
Margarita L Alvarez-VilchezSociedad Científica de Estudiantes de Medicina, Universidad Peruana Los Andes, Huancayo, Peru.
Janith P De la Cruz-GalánSociedad Científica de Estudiantes de Medicina Veritas, Universidad de San Martín de Porres, Lambayeque, Peru.
Yubely Gálvez-GuadalupeSociedad Científica de Estudiantes de Medicina, Universidad Privada Antenor Orrego, Trujillo, Peru.
Edwin D Garcia-MuñozEscuela de Medicina, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas, Chachapoyas, Peru.
Greysi Cerron-DagaUniversidad Nacional Daniel Alcides Carrión, Pasco, Peru.
Virgilio E Failoc-RojasUniversidad San Ignacio de Loyola, Lima, Peru.
Mario J Valladares-GarridoUniversidad Cesar Vallejo, Piura, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The pandemic of COVID-19 continues to impact people worldwide, with more than 755 million confirmed cases and more than 6.8 million reported deaths. Although two types of treatment, antiviral and immunomodulatory therapy, have been approved to date, vaccination has been the best method to control the spread of the disease. Objective: To explore factors associated with the intention to be vaccinated with the COVID-19 booster dose in Peru. Material and Methods: Cross-sectional study, using virtual and physical surveys of adults with two or more doses of COVID-19 vaccine, where the dependent variable was the intention to be vaccinated (IBV) with the booster dose. We calculated prevalence ratios with 95% confidence intervals, using generalized linear models of the Poisson family with robust varying, determining associations between sociodemographic, clinical, and booster dose perception variables. Results: Data from 924 adults were analyzed. The IBV of the booster doses was 88.1%. A higher prevalence was associated with being male (aPR = 1.05; 95% CI [1.01-1.10]), having a good perception of efficacy and protective effect (PR = 3.69; 95% CI [2.57-5.30]) and belonging to the health sector (PR = 1.10; 95% CI [1.04-1.16]). There was greater acceptance of the recommendation of physicians and other health professionals (aPR = 1.40; 95% CI [1.27-1.55]). Conclusions: Factors associated with higher IBV with booster dose include male gender, health sciences, physician recommendation, and good perception of efficacy.

Indexed as

COVID-19AdultCOVID-19 VaccinesCross-Sectional StudiesFemaleHumansIntentionMalePeruCOVID-19 VaccinesCOVID-19COVID-19 vaccine boosterPeruSARS-CoV-2Vaccination refusal

Identifiers

PMID38563006
PMCPMC10984177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.